ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan

ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based on development and commercial milestones plus tiered royalties on sales in percentages ranging up to low twentiesZenyaku Kogyo, a leading J...

Related Keywords

Japan ,Ukraine ,Singapore ,California ,United States ,Tokyo ,Russia ,Japanese ,Ashleyr Robinson ,Carl Firth ,Koichi Hashimoto ,Emma Thompson ,Zenyaku Kogyo ,Nasdaq ,Chugai Pharmaceutical Co Ltd ,Pharmaceuticals Nasdaq ,Linkedin ,Decision Resources Group ,Globenewswire Inc ,Zenyaku Kogyo Co Ltd ,Zenyaku Holdings Co Ltd ,Zenyaku Holdings ,Company Annual Report On Form ,Commission File No ,Spurwing Communications ,Exchange Commission ,Lifesci Advisors ,Chief Executive Officer ,B Cell Non Hodgkin ,Commission File ,Annual Report ,Resources Group ,Atopic Dermatitis Disease Landscape ,Sci Advisors ,